{
  "id": 13257480,
  "title": "Immunovant chief legal officer Van Tuyl sells $42,543 in stock",
  "url": "https://urgent.news/2026/10/09/immunovant-chief-legal-officer-van-tuyl-sells-42-543-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T23:31:27.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/immunovant-chief-legal-officer-van-tuyl-sells-42543-in-stock-93CH-4941839"
  },
  "original_language": "en",
  "account": "Immunovant's Chief Legal Officer, Christopher Van Tuyl, recently sold 1,327 shares of company stock, totaling $42,543. The sale was necessary to cover tax withholding obligations related to the vesting and settlement of restricted stock units. This transaction occurred on October 7, 2026, as shares of Immunovant declined about 9% over the previous week, trading at $30.47. Despite this recent weakness, the stock has seen a strong 74% return over the past year. Immunovant's IMVT-1402 drug candidate failed to meet its primary endpoint in a clinical trial for cutaneous lupus erythematosus, leading to the discontinuation of development for this indication. Roivant Sciences, Immunovant's parent company, reported a first-quarter loss, with earnings per share at -$0.75, not meeting analyst expectations of -$0.60. The loss was attributed to increased spending on research and development in preparation for the second half of 2026. Despite these developments, H.C. Wainwright maintains a Buy rating on Immunovant with a price target of $41.00, while Cantor Fitzgerald keeps an Overweight rating, reflecting continued confidence in the company.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}